BCL2 and cancer: In conclusion, we herein prove that, in addition to acting as a pan-BCL-2 inhibitor, Obatoclax triggers cancer cell apoptosis through an additional mechanism of action that involves suppression of WNT/β-catenin signaling to downregulate survivin (Figure 7).